MAPK Inhibitors Restore CAR T-Cell Target in Thyroid Cancer Models
Trametinib and dabrafenib increased TSHR expression and improved the activity of CAR T cells in a patient-derived model of anaplastic thyroid cancer
-
1
MAPK inhibitors can enhance CAR T-cell therapy effectiveness in thyroid cancer by restoring TSHR expression on tumor cells.
-
2
Combining MAPK inhibitors with TSHR-directed CAR T cells improved tumor control and survival in preclinical mouse models.
-
3
TSHR expression is crucial for CAR T-cell activity, as low expression limits treatment efficacy against aggressive thyroid cancers.
-
4
Concurrent treatment with MAPK inhibitors and CAR T cells resulted in stronger tumor control than either treatment alone.
-
5
Further studies are planned to support a phase I trial of TSHR-directed CAR T cells combined with MAPK inhibitors.
